CRISPR/Cas9-mediated conversion of human platelet alloantigen allotypes

Blood

Volumn 127, Issue 6, 2016, Pages 675-680

  Zhang, Nanyan ^a   Zhi, Huiying ^a   Curtis, Brian R ^a   Rao, Sridhar ^a,b   Jobaliya, Chintan ^c   Poncz, Mortimer ^d   French, Deborah L ^c,e   Newman, Peter J ^a,b,d  

^a BLOOD RESEARCH INSTITUTE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c Perelman Center for Cell and Molecular Therapeutics   (United States)

^d Department of Pediatrics ^*  (United States)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; AMINO ACID; BETA3 INTEGRIN; CRISPR ASSOCIATED PROTEIN 9; FIBRINOGEN RECEPTOR; GENOMIC DNA; RESTRICTION ENDONUCLEASE; UNCLASSIFIED DRUG; 1A ALLOANTIGEN, HUMAN; ALLOANTIBODY; CRISPR ASSOCIATED PROTEIN; EPITOPE; HUMAN PLATELET ANTIGEN 1B; THROMBOCYTE ANTIGEN;

ARTICLE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CRISPR CAS SYSTEM; DNA SEQUENCE; FLOW CYTOMETRY; GENOTYPE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MEGAKARYOBLAST; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; THROMBOCYTE; WESTERN BLOTTING; CELL CULTURE; GENETICS; IMMUNOLOGY; METABOLISM; NUCLEOTIDE SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTIGENS, HUMAN PLATELET; BASE SEQUENCE; CELLS, CULTURED; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; CRISPR-ASSOCIATED PROTEINS; EPITOPES; HUMANS; INTEGRIN BETA3; ISOANTIBODIES; ISOANTIGENS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PLATELET MEMBRANE GLYCOPROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84959330331     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-10-675751     Document Type: Article

References (50)

1. Aster RH. Studies of the fate of platelets in rats and man. Blood. 1969;34(2):117-128.
2. Newman PJ, McFarland JG, Aster RH. The Alloimmune Thrombocytopenias. In: Loscalzo J, Schafer AI, eds. Thrombosis and Hemorrhage. Philadelphia: Lippincott Williams and Wilkins; 2003:441-456.
3. Williamson LM, Hackett G, Rennie J, et al. The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PlA1, Zwa) as determined by antenatal screening. Blood. 1998;92(7):2280-2287.
4. Kjeldsen-Kragh J, Killie MK, Tomter G, et al. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia. Blood. 2007;110(3):833-839.
5. Giovangrandi Y, Daffos F, Kaplan C, Forestier F, Mac Aleese J, Moirot M. Very early intracranial haemorrhage in alloimmune fetal thrombocytopenia. Lancet. 1990;336(8710): 310.
6. Bonacossa IA, Jocelyn LJ. Alloimmune thrombocytopenia of the newborn: neurodevelopmental sequelae. Am J Perinatol. 1996;13(4):211-215.
7. Dreyfus M, Kaplan C, Verdy E, Schlegel N, Durand-Zaleski I, Tchernia G; Immune Thrombocytopenia Working Group. Frequency of immune thrombocytopenia in newborns: A prospective study. Blood. 1997;89(12): 4402-4406.
8. Spencer JA, Burrows RF. Feto-maternal alloimmune thrombocytopenia: A literature review and statistical analysis. Aust N Z J Obstet Gynaecol. 2001;41(1):45-55.
9. Turner ML, Bessos H, Fagge T, et al. Prospective epidemiologic study of the outcome and costeffectiveness of antenatal screening to detect neonatal alloimmune thrombocytopenia due to anti-HPA-1a. Transfusion. 2005;45(12): 1945-1956.
10. Bussel J. Diagnosis and management of the fetus and neonate with alloimmune thrombocytopenia. J Thromb Haemost. 2009; 7(Suppl 1):253-257.
11. Van Loghem JJ J, Dorfmeijer H, Van Hart M, Schreuder F. Serological and genetical studies on a platelet antigen (Zw). Vox Sang. 1959;4(2): 161-169.
12. Shulman NR, Aster RH, Pearson HA, Hiller MC. Immunoreactions involving platelet. VI. Reactions of maternal isoantibodies responsible for neonatal purpura. Differentiation of a second platelet antigen system. J Clin Invest. 1962;41(5): 1059-1069.
13. Newman PJ, Derbes RS, Aster RH. The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J Clin Invest. 1989;83(5):1778-1781.
14. Curtis BR. Recent progress in understanding the pathogenesis of fetal and neonatal alloimmune thrombocytopenia. Br J Haematol. 2015;171(5): 671-682.
15. McFarland JG, Aster RH, Bussel JB, Gianopoulos JG, Derbes RS, Newman PJ. Prenatal diagnosis of neonatal alloimmune thrombocytopenia using allele-specific oligonucleotide probes. Blood. 1991;78(9):2276-2282.
16. Curtis BR. Genotyping for human platelet alloantigen polymorphisms: Applications in the diagnosis of alloimmune platelet disorders. Semin Thromb Hemost. 2008;34(6):539-548.
17. Le Toriellec E, Chenet C, Kaplan C. Safe fetal platelet genotyping: new developments. Transfusion. 2013;53(8):1755-1762.
18. An QX, Li CY, Xu LJ, et al. High-throughput simultaneous genotyping of human platelet antigen-1 to -16 by using suspension array. Transfusion. 2013;53(11):2722-2728.
19. Skogen B, Bellissimo DB, Hessner MJ, et al. Rapid determination of platelet alloantigen genotypes by polymerase chain reaction using allele-specific primers. Transfusion. 1994;34(11): 955-960.
20. Vassallo RR Jr. New paradigms in the management of alloimmune refractoriness to platelet transfusions. Curr Opin Hematol. 2007; 14(6):655-663.
21. Bussel JB, Sola-Visner M. Current approaches to the evaluation and management of the fetus and neonate with immune thrombocytopenia. Semin Perinatol. 2009;33(1):35-42.
22. Pacheco LD, Berkowitz RL, Moise KJ Jr, Bussel JB, McFarland JG, Saade GR. Fetal and neonatal alloimmune thrombocytopenia: A management algorithm based on risk stratification. Obstet Gynecol. 2011;118(5):1157-1163.
23. Si-Tayeb K, Noto FK, Sepac A, et al. Generation of human induced pluripotent stem cells by simple transient transfection of plasmid DNA encoding reprogramming factors. BMC Dev Biol. 2010;10: 81.
24. Mills JA, Paluru P, Weiss MJ, Gadue P, French DL. Hematopoietic differentiation of pluripotent stem cells in culture. Methods Mol Biol. 2014; 1185:181-194.
25. Paluru P, Hudock KM, Cheng X, et al. The negative impact of Wnt signaling on megakaryocyte and primitive erythroid progenitors derived from human embryonic stem cells. Stem Cell Res (Amst). 2014;12(2):441-451.
26. Wilcox DA, Olsen JC, Ishizawa L, Griffith M, White GC II. Integrin alphaIIb promoter-targeted expression of gene products in megakaryocytes derived from retrovirus-transduced human hematopoietic cells. Proc Natl Acad Sci USA. 1999;96(17):9654-9659.
27. Ran FA, Hsu PD, Lin CY, et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell. 2013;154(6):1380-1389.
28. Shen B, Zhang W, Zhang J, et al. Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. Nat Methods. 2014;11(4):399-402.
29. Harrison CR, Curtis BR, McFarland JG, Huff RW, Aster RH. Severe neonatal alloimmune thrombocytopenia caused by antibodies to human platelet antigen 3a (Baka) detectable only in whole platelet assays. Transfusion. 2003;43(10): 1398-1402.
30. Ouwehand WH. The dilemma of screening for antibodies against low-frequency human platelet antigens. Transfusion. 2005;45(3):288-289.
31. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007; 131(5):861-872.
32. Ohnuki M, Takahashi K, Yamanaka S. Generation and characterization of human induced pluripotent stem cells. Curr Protoc Stem Cell Biol. 2009; Chapter 4:Unit 4A.2.
33. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318(5858): 1917-1920.
34. Choi KD, Vodyanik MA, Slukvin II. Generation of mature human myelomonocytic cells through expansion and differentiation of pluripotent stem cell-derived lin-CD341CD431CD451 progenitors. J Clin Invest. 2009;119(9): 2818-2829.
35. Kennedy M, D'Souza SL, Lynch-Kattman M, Schwantz S, Keller G. Development of the hemangioblast defines the onset of hematopoiesis in human ES cell differentiation cultures. Blood. 2007;109(7):2679-2687.
36. Sullivan SK, Mills JA, Koukouritaki SB, et al. Highlevel transgene expression in induced pluripotent stem cell-derived megakaryocytes: correction of Glanzmann thrombasthenia. Blood. 2014;123(5): 753-757.
37. Nakamura S, Takayama N, Hirata S, et al. Expandable megakaryocyte cell lines enable clinically applicable generation of platelets from human induced pluripotent stem cells. Cell Stem Cell. 2014;14(4):535-548.
38. Thon JN, Mazutis L, Wu S, et al. Platelet bioreactor-on-a-chip. Blood. 2014;124(12): 1857-1867.
39. Feng Q, Shabrani N, Thon JN, et al. Scalable generation of universal platelets from human induced pluripotent stem cells. Stem Cell Rep. 2014;3(5):817-831.
40. Wang Y, Hayes V, Jarocha D, et al. Comparative analysis of human ex vivo-generated platelets vs megakaryocyte-generated platelets in mice: A cautionary tale. Blood. 2015;125(23):3627-3636.
41. Karginov FV, Hannon GJ. The CRISPR system: small RNA-guided defense in bacteria and archaea. Mol Cell. 2010;37(1):7-19.
42. Mali P, Esvelt KM, Church GM. Cas9 as a versatile tool for engineering biology. Nat Methods. 2013;10(10):957-963.
43. Cong L, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339(6121):819-823.
44. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8(11): 2281-2308.
45. Ding Q, Regan SN, Xia Y, Oostrom LA, Cowan CA, Musunuru K. Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs. Cell Stem Cell. 2013;12(4):393-394.
46. Wang H, Yang H, Shivalila CS, et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell. 2013;153(4):910-918.
47. Nielsen LS, Svejgaard A. HL-A immunization and HL-A types in pregnancy. Tissue Antigens. 1972; 2(4):316-327.
48. Aster RH, Szatkowski N, Liebert M, Duquesnoy RJ. Expression of HLA-B12, HLA-B8, w4, and w5 on platetelets. Transplant Proc. 1977;9(4): 1695-1696.
49. Lancet D, Parham P, Strominger JL. Heavy chain of HLA-A and HLA-B antigens is conformationally labile: A possible role for b 2-microglobulin. Proc Natl Acad Sci USA. 1979;76(8):3844-3848.
50. Gras C, Schulze K, Goudeva L, Guzman CA, Blasczyk R, Figueiredo C. HLA-universal platelet transfusions prevent platelet refractoriness in a mouse model. Hum Gene Ther. 2013;24(12): 1018-1028.